Perspectives from the American Society of Clinical Oncology 2014 Conference: Breast cancer highlights

Future Oncology

Volumn 10, Issue 12, 2014, Pages 1897-1899

  Crozier, Jennifer A ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

adjuvant therapy; ASCO; breast cancer; chemotherapy; genomics; highlights

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CHRONIC PATIENT; CONFERENCE PAPER; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MEDICAL SOCIETY; ONCOLOGY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; TRENDS; UNITED STATES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MEDICAL ONCOLOGY; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84922660894     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.151     Document Type: Conference Paper

References (4)

1. Piccart-Gebhart M, Holmes AP, Baselga J et al. First results from the Phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J. Clin. Oncol. 32(5), Abstract LBA4 (2014).
2. Miller K, O'Neill AM, Dang CT et al. Bevacizumab (BV) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J. Clin. Oncol. 32(5), Abstract 500 (2014).
3. Pagani O, Regan MM, Walley B et al. Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials. J. Clin. Oncol. 32(5), Abstract LBA1 (2014).
4. Perez EA, Thompson EA, Anderson SK et al. Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. J. Clin. Oncol. 32(5), Abstract 509 (2014).